贝达药业，宣布赴香港IPO，重启A+H上市 | A股公司香港上市

Group 1 - The core point of the article is that Beida Pharmaceutical (300558.SZ) plans to issue overseas listed shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its capital strength and competitiveness while advancing its internationalization process [2] - Beida Pharmaceutical will consider the interests of existing shareholders and the conditions of domestic and foreign capital markets when selecting the appropriate timing and issuance window for the listing [2] - The company has previously attempted to list in Hong Kong, submitting its prospectus in February 2021 and again in December 2021, but both attempts were unsuccessful [2] Group 2 - Beida Pharmaceutical, founded in 2003, focuses on innovative drug research and development with independent intellectual property rights, and has eight drugs currently on the market [3] - The company was listed on the Shenzhen Stock Exchange on November 7, 2016, and as of September 10, 2025, its total market capitalization is approximately 30.259 billion RMB [3][4] - The company's notable products include various cancer treatment drugs, such as the hydrochloride erlotinib tablets (Kaimena®) and the hydrochloride ensartinib capsules (Beimana®) [3]